KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Non-Current Assets (2017 - 2025)

Moderna (MRNA) has disclosed Non-Current Assets for 9 consecutive years, with $5.5 billion as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets rose 157.28% to $5.5 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.3 billion, a 90.08% increase, with the full-year FY2024 number at $6.0 billion, up 158.53% from a year prior.
  • Non-Current Assets was $5.5 billion for Q3 2025 at Moderna, up from -$6.2 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $12.4 billion in Q4 2022 to a low of -$14.3 billion in Q3 2022.
  • A 5-year average of -$1.0 billion and a median of $991.0 million in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 1036.13% in 2022, then tumbled 207.66% in 2023.
  • Moderna's Non-Current Assets stood at $8.6 billion in 2021, then surged by 44.53% to $12.4 billion in 2022, then crashed by 183.09% to -$10.3 billion in 2023, then skyrocketed by 158.53% to $6.0 billion in 2024, then dropped by 8.37% to $5.5 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Non-Current Assets are $5.5 billion (Q3 2025), -$6.2 billion (Q2 2025), and $6.0 billion (Q4 2024).